Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avanir

This article was originally published in The Tan Sheet

Executive Summary

Firm files New Drug Submission with the Canadian Therapeutic Products Programme (TPP) for OTC sale of docosanol 10% cream. Avanir estimates approximately 15 months for TPP review, with marketing authorization possible in the first quarter 2002. In July, Avanir's Abreva docosanol 10% cream received FDA clearance as an OTC cold sore treatment (1"The Tan Sheet" July 31, p. 3). SmithKline Beecham holds the marketing rights in the U.S. and Canada

You may also be interested in...



Avanir Abreva Cold Sore/Fever Blister Cream Approved By FDA

Avanir Pharmaceuticals' 10% docosanol cream was approved July 25 for the treatment of cold sores and fever blisters. The product, which FDA's approval letter indicates will be marketed as Abreva Cream, will be the first FDA-approved OTC cold sore and fever blister treatment.

People In Brief

Perrigo promotes in pricing, planning

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel